Methylation Risk Scores
The article says the Harvard/UK Biobank dataset has already shown that the epigenome predicts disease onset better than traditional biomarkers. Methylation Risk Scores would use full epigenomic signatures to estimate probabilities of contr…
1 sources - 3 claims
The article says the Harvard/UK Biobank dataset has already shown that the epigenome predicts disease onset better than traditional biomarkers. Methylation Risk Scores would use full epigenomic signatures to estimate probabilities of contracting specific diseases. The planned next phase is to move from inferring biomarker levels to directly predicting disease likelihood.